Author name: Ying Mak

Why don’t we trust people’s lived-experience of fatigue?

15 September 2023 / Insights

Fatigue is the sort of subjective phenomenological experience that has plagued philosophers and neuroscientists for centuries. For those with lived experience, fatigue can be debilitating, and patients can be left feeling ignored and maligned. Despite over 17 million people across Europe1, reporting symptoms of Long Covid, with fatigue being the most common symptom, there is …

Why don’t we trust people’s lived-experience of fatigue? Read More »

Speech based biomarkers for monitoring progressive changes in Alzheimer’s disease

14 September 2023 / Insights

A speech based composite which tracks change in AD over time was recently developed and piloted through a collaboration between Winterlight Labs and Genentech.

Speech is a rich source of clinical information when assessing and monitoring Alzheimer’s Disease. Natural language processing technologies, like those developed by Winterlight Labs, can objectively quantify speech and enable its use as a novel endpoint in drug development.

Highlights from AAIC 2023

14 September 2023 / Insights

The headline from this year’s AAIC in Amsterdam is undoubtedly the announcement of the results of TRAILBLAZER-ALZ-2, a phase 3 trial of Eli Lilly’s new drug Donanemab with 1,800 participants. Donanemab is an antibody-based drug that works by breaking down already-formed amyloid plaques that build up in Alzheimer’s disease (AD), rather than interfering with their production.

Frontiers in Neurology | Revolutionising the detection of cognitive impairment in multiple sclerosis with technology

4 July 2023 / Publications & posters

Publications & posters Back to resource centre 11 January 2023 Revolutionising the detection of cognitive impairment in multiple sclerosis with technology Cognitive dysfunction is a leading cause of disability in multiple sclerosis (MS), yet practical restraints mean it often goes unassessed in routine clinical care. Promising new research, published in Frontiers in Neurology, suggests the Cambridge Neuropsychological Test Automated Battery

Frontiers in Psychiatry | Using affective cognition to enhance precision psychiatry

5 July 2023 / Publications & posters

Publications & posters Back to resource centre 11 January 2023 Using affective cognition to enhance precision psychiatry Precision psychiatry is a promising new approach that seeks to improve outcomes in highly heterogeneous clinical populations. Frontiers in Psychiatry recently published an interesting opinion piece on “Using Affective Cognition to Enhance Precision Psychiatry” 1 by Dr Jack Cotter, Clinical Science Team Lead at Cambridge

CANTAB Mobile: experience of use of a digital memory screening tool in primary care

5 July 2023 / Publications & posters

Publications & posters Back to resource centre 11 January 2023 CANTAB Mobile: experience of use of a digital memory screening tool in primary care Early identification of memory complaints in clinical settings can aid identification of deficits, or reassurance, and can support care planning and management. CANTAB Mobile combines a sensitive touchscreen memory test, with a depression screen to differentiate

Evaluating the challenges and benefits of fully decentralized and hybrid clinical trials

22 June 2023 / Case studies

Back to resource centre Evaluating the challenges and benefits of fully decentralized and hybrid clinical trials A pan-European interventional study to enrol Diabetes Mellitus (DM) patientsThe RADIAL concept study aims to generate delivering scientific evidence and data on the benefits and challenges of running a DCT Clinpal is the core platform for this in a 3-arm (conventional, hybrid, remote) clinical trial

Study in Psoriasis

22 June 2023 / Case studies

Back to resource centre A digitised version of the SAPASI instrument, allowing researchers to monitor and record moderate-to-severe plaque psoriasis in clinical trial patients Leveraging Wake Forest’s validated diagnostic tool, the Self-administered Psoriasis Area Severity Index (SAPASI) ePRO prompts patients using the standard Clinpal app on their bring-your-own devices, at protocol-specified time intervals, to manually mark where their psoriasis is on

A patient-centric, clinician focused and sponsor efficient decentralised clinical trials

Validation Study to Assess the Adherence of RA Patients Taking MTX

22 August 2023 / Case studies

Back to resource centre Validation Study to Assess the Adherence of RA Patients Taking MTX A multi-centre psychometric validation study, led by Roche, to validate a PRO tool (MEQ) to assess medication adherence in rheumatoid arthritis (RA) for patients being treated with Methotrexate (MTX).Once recruited, patients completed the MEQ and two generic compliance questionnaires to self-reported adherence. Physicians of the

CANTAB Recruit: A quicker, more cost-effective way of finding the right patients for clinical trials

22 June 2023 / Case studies

Back to resource centre CANTAB Recruit: A quicker, more cost-effective way of finding the right patients for clinical trials Key achievementsUsing the online CANTAB Recruit assessment our customer screened out over 85% of their participants who would be ineligible for their Alzheimer’s trial, saving time and money.High compliance rates of 90% were seen when screening an aging population taking assessments

Cambridge Cognition
Scroll to Top